Kidney cancer

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
torsdag, maj 9, 2024
Immunotherapy, FDA, Society, Nivolumab, Research, National Cancer Institute, Bevacizumab, PD-1, ASCO, Journal, Therapy, Liver, Patient, NCI, SITC, RCC, AACR, Kidney cancer, FFA, Growth, HCC, Pharmaceutical industry

BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update.
  • These data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022.
  • Tempest ended the quarter with $32.3 million in cash and cash equivalents, compared to $39.2 million on December 31, 2023.
  • Based on its current cash and operating plan, Tempest expects to have sufficient resources to fund operations into the second quarter of 2025.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
måndag, maj 6, 2024
FDA, Total, ITK, Research, PTCL, PR, Doctor of Philosophy, Webcast, Fungal infection, Atopic dermatitis, RCC, Lymphoma, Vanderbilt University Medical Center, Lung cancer, Conference call, Kidney cancer, Conference, CRS, Peripheral, Assistant, PRS, NSCLC, Patient, Safety, Pembrolizumab, Modified, CTCL, Time management, Clinical trial, Division, Sale, A2A, Adenosine, HNSCC, T-cell lymphoma, Nivolumab, Ipilimumab, B-cell lymphoma, Disease, ALCL, Physician, Head, PTCL-NOS, Pharmaceutical industry

BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
  • Corvus anticipates initiating a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL in the third quarter of 2024.
  • Corvus will host a conference call and webcast today, Monday, May 6, 2024, at 4:30 p.m.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the first quarter 2024 financial results.

Global $46.7B Cancer Biomarkers Market Outlook, 2035: MET Biomarkers Lead the Charge, Driven by Rising Incidence of Lung Cancer and Drug Development - ResearchAndMarkets.com

Retrieved on: 
onsdag, maj 8, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Foundation Medicine, MSI, Lung cancer, Breast cancer, Blood, AI, MDPI, Skin cancer, Agilent Technologies, Prostate cancer, Biomarker, ALK, Kidney cancer, EGFR, OncoDNA, Cancer, Bladder cancer, Tempus, Son, Non-small-cell lung cancer, Frontiers Media, HER2, Colorectal cancer, Turbine, Thyroid cancer, ARUP Laboratories, Roche, Database, Therapy, Merck, NSCLC, Thermo Fisher Scientific, Nature, Publication, Laboratory, Survival, Insurance, BioMed Central, Nature Portfolio, Incidence, Drug development, Liver cancer, Liquid biopsy, MET, NTRK, CK Life Sciences, Endometrial cancer, Actuate, PD-L1, Patient, Gastrointestinal cancer, Physician, Neoplasm, Head, Medical imaging

Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.

Key Points: 
  • Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.
  • Currently, the market is driven by breast cancer biomarkers and lung cancer biomarkers; however, in the coming future, we anticipate cancer biomarker market for leukemia to grow at a significant pace.
  • The market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in the cancer biomarkers market.
  • It is worth mentioning that Merck is conducting the maximum number of trials in this industry for various cancer indications, including bladder cancer, breast cancer, colorectal cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer and skin cancer.

ArsenalBio Announces Presentation of Four Abstracts at ASGCT Annual Meeting Highlighting New Mechanisms for Leveraging CAR T Cells to Address Solid Tumor Cancers

Retrieved on: 
måndag, maj 6, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, ISH, PSMA, CD3, CA9, Payload, CRISPR, SPA, Risk, Tissue, ICT, Abstract, Immunosuppression, Cytokine, Tumor microenvironment, Cell, Research, Primer, Downregulation and upregulation, Engineering, DNA, Science, Gene, Society, Neoplasm, Antigen, Messenger, Information and communications technology, Immune system, Kidney cancer, In situ hybridization, Ovarian cancer, Vaccine

These data highlight the portfolio of solutions ArsenalBio is developing to address unmet need in solid tumor cancers, including those currently being studied as potential treatments for ovarian cancer ( NCT05617755 ) and kidney cancer ( NCT06245915 ).

Key Points: 
  • These data highlight the portfolio of solutions ArsenalBio is developing to address unmet need in solid tumor cancers, including those currently being studied as potential treatments for ovarian cancer ( NCT05617755 ) and kidney cancer ( NCT06245915 ).
  • It integrates an “AND” logic gate designed to limit off-tumor toxicity through a requirement for dual tumor antigen recognition.
  • T cell exhaustion from chronic antigen stimulation and an immunosuppressive tumor microenvironment limits the efficacy of T cell therapies used to treat solid tumors.
  • This research used CRISPR/Cas9-based screening, paired with deep sequencing, to identify intrinsic genetic perturbations that can prevent T cell exhaustion.

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Retrieved on: 
fredag, april 26, 2024
Cancer, Safety, Regenerative medicine, TS, Metastasis, Trial of the century, Doctor of Philosophy, Development, Disease, CIRM, Autoimmune disease, Kite Pharma, Research and development, Patient, RCC, CD70, AACR, Clinical trial, Kidney cancer, Therapy, SAN, Pharmaceutical industry

It is a disease in need of innovation as current therapies are based on a few mechanistic targets and complete response rates are low.

Key Points: 
  • It is a disease in need of innovation as current therapies are based on a few mechanistic targets and complete response rates are low.
  • The grant will support the ongoing Phase 1 TRAVERSE trial which assesses safety, tolerability and preliminary efficacy of ALLO-316 in advanced RCC that has progressed despite standard therapy.
  • Additionally, the grant will support translational and clinical analyses to inform a recommended Phase 2 regimen.
  • A more comprehensive data update from the ongoing trial is planned for later in 2024.

NCCN Foundation Announces Recipients for 2024 Young Investigator Awards Honoring Future Leaders of Cancer Research

Retrieved on: 
måndag, april 15, 2024
YIA, Genetics, NCCN, Pfizer, Daiichi Sankyo, Abstract, Merck & Co., National Comprehensive Cancer Network, MD, Conference, Research, Prostate cancer, Kidney cancer, Merck, Cervical cancer

PLYMOUTH MEETING, Pa., April 15, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® today announced five winners for the 2024 NCCN Foundation Young Investigator Awards (YIA). These annual awards honor some of the most promising new oncology researchers from across NCCN's Member Institutions. Investigator selection and project oversight is organized through the NCCN Oncology Research Program (ORP). Funding of up to $150,000 over two years per awardee will be provided by the NCCN Foundation.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 15, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® today announced five winners for the 2024 NCCN Foundation Young Investigator Awards (YIA).
  • Investigator selection and project oversight is organized through the NCCN Oncology Research Program (ORP).
  • Funding of up to $150,000 over two years per awardee will be provided by the NCCN Foundation .
  • The 2024 NCCN Foundation Young Investigator Award recipients are:
    A Phase 2 Trial of IO102/IO103 and Nivolumab-Relatlimab Fixed-dose Combination in Previously Untreated, Unresectable Melanoma
    "The YIA program is a cornerstone of our work to advance cancer care," said Patrick Delaney, Executive Director, NCCN Foundation.

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Retrieved on: 
tisdag, april 9, 2024
HCC, Head, Growth, Immunotherapy, Patient, Tumor microenvironment, Cancer, Renal cell carcinoma, AACR, Bevacizumab, RCC, Neoplasm, Therapy, Nivolumab, ASCO, Tempest, Kidney cancer

These new data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022.

Key Points: 
  • These new data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022.
  • “Preclinical data presented at AACR further demonstrate that TPST-1120 has the potential to positively transform the tumor microenvironment and expand the activity of anti-tumor immunity in kidney cancer,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest.
  • In preclinical models of renal cell carcinoma (RCC), treatment with TPST-1120 reduced tumor growth by 52%-56% as monotherapy.
  • Additional improvement in anti-cancer activity was demonstrated in combination treatment with standard first-line RCC cabozantinib or anti-PD1 therapy, where tumor inhibition was 81% and 74%, respectively.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
tisdag, mars 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

BostonGene Announces Acceptance of Eight Abstracts to be Presented at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
tisdag, april 2, 2024
Biotechnology, Technology, AIDS, Health, General Health, Oncology, Health Technology, Medical Devices, Artificial Intelligence, Genetics, Clinical Trials, B-cell lymphoma, TLS, HIV, Patient, Lung, RNA, Abstract, AACR, Blood, San Diego Convention Center, DLBCL, Kidney cancer

BostonGene , a leading provider of AI-driven molecular and immune profiling solutions, today announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which will be held from April 5 - 10, at the San Diego Convention Center in San Diego, CA.

Key Points: 
  • BostonGene , a leading provider of AI-driven molecular and immune profiling solutions, today announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which will be held from April 5 - 10, at the San Diego Convention Center in San Diego, CA.
  • BostonGene will exhibit at booth #847.
  • BostonGene, together with its collaborators, will deliver presentations on various topics, including the feasibility and utility of using comprehensive genomic and transcriptomic analysis for patients with blood and solid cancers, RNA-based models for TLS prediction in both lung and pancreatic cancers, a transcriptomic-based model to distinguish sarcomatoid features in kidney cancer and the use of comprehensive molecular profiling to evaluate the impact of race and HIV status on the genetic landscape of patients with diffuse large B-cell lymphoma (DLBCL) in southern Africa.
  • Details of BostonGene’s poster presentations at the AACR Annual Meeting are below:

Life Guard Imaging Celebrates Patient Cindy Withers Throwing Ceremonial First Pitch at New York Yankees Spring Training Game

Retrieved on: 
onsdag, mars 13, 2024
Medical Devices, Baseball, Sports, Entertainment, Cardiology, Philanthropy, Events, Concerts, Health, Other Philanthropy, Oncology, Organization, Baltimore Orioles, Patient, Lifeguard, Withers, Business development, Cancer, New York Yankees, Multimedia, Family, Courage, Kidney cancer

Life Guard Imaging proudly celebrated the remarkable journey of patient and kidney cancer survivor Cindy Withers at the New York Yankees Spring Training game against the Baltimore Orioles on March 11, 2024.

Key Points: 
  • Life Guard Imaging proudly celebrated the remarkable journey of patient and kidney cancer survivor Cindy Withers at the New York Yankees Spring Training game against the Baltimore Orioles on March 11, 2024.
  • Life Guard Imaging, a leading provider of preventative imaging services, was honored to serve as the presenting sponsor for this inspiring occasion.
  • "We are thrilled to see Cindy Withers take center stage at the Yankees Spring Training game," said Martin Gramatica, VP of Business Development for Life Guard Imaging.
  • Life Guard Imaging remains dedicated to preventative healthcare and supporting patients like Cindy Withers in their fight against cancer and other health conditions.